Leah Natasha Klapper

Ramot at Tel Aviv University Ltd. operates as a technology transfer company of Tel Aviv University (TAU). It provides legal and commercial frameworks for inventions made by TAU faculty, students, and researchers. The firm licenses the university's intellectual property to third parties through agreements; facilitates collaborative research partnerships between business partners and TAU researchers; establishes a company; and forms joint ventures that promote TAU technologies. The company was founded in 1973 and is headquartered in Tel Aviv, Israel.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

Hadasit Medical Research Services & Development Ltd. operates as technology transfer company of Hadassah Medical Center in Jerusalem. It identifies, protects, nurtures and commercializes the discoveries made at Hadassah Medical Center. The company's product include Doxil, Periochip, Travelan, Granagard, and Insupad. The company was founded on December 7, 1986 and is headquartered in Jerusalem, Israel.

BioJerusalem engages in the provision of financial assistance to life sciences companies choosing to launch operations in Jerusalem, which are eligible for prime financial support incentives and are given special preference. The company is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

ImmPACT-Bio Ltd. develops therapies to treat cancer. Its chimeric antigen receptor T-cell (CAR-T) therapy addresses the need to differentiate cancerous from non-cancerous tissues. The company was founded by Gideon Gross in April 2017 and is headquartered in Nes Ziona, Israel.

DreaMed Diabetes Ltd. is a medical technology company based in Petach Tikva, Israel. DreaMed Diabetes is currently commercializing its endo.digital AI-based clinical decision support system for diabetes management. The endo.digital platform has FDA clearance for patients with type 1 diabetes using continuous glucose monitors or self-monitoring blood glucose monitor devices and insulin pumps. The technology also received expanded FDA clearance to include patients with type 1 or type 2 diabetes on multiple daily injections. The Israeli company's first product, an artificial pancreas technology, was licensed to Medtronic and incorporated into its 780g insulin pump technology. The company provides personalized diabetes treatment optimization solutions and was founded in 2014 by Revital Nimri, Tadej Battelino, Eran Atlas, Thomas Danne, and Ido Muller. Eran Atlas has been the CEO since 2014.

Biomica Ltd. engages in the provision of biopharmaceutical services. Its technology focuses on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. The company was founded by Yehuda Ringel in 2017 and is headquartered in Rehovot, Israel.